Sarepta’s controversial Duchenne muscular dystrophy drug was contested right up to approval
September 19, 2016 at 12:48 PM EDT
One final twist was “highly unusual,” the FDA’s top leader said.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|